Advanced in Pure Red Cell Aplasia

Dr. Ian Rabinowitz

Hematology | Oncology
Unm Cancer Ctr, 1201 Camino De Salud Ne, 
Albuquerque, NM 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in Pure Red Cell Aplasia
Unm Cancer Ctr, 1201 Camino De Salud Ne, 
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ian Rabinowitz is a Hematologist and an Oncologist in Albuquerque, New Mexico. Dr. Rabinowitz is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Ependymoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. Rabinowitz is currently accepting new patients.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NM
Languages Spoken
English
French
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Unm Cancer Ctr, 1201 Camino De Salud Ne, Albuquerque, NM 87131

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
INST UNM 1601: Compassionate Use of BYL 719 Alpelisib
INST UNM 1601: Compassionate Use of BYL 719 Alpelisib
Enrollment Status: No_longer_available
Publish Date: January 11, 2024
Intervention Type: Drug
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 13 Less Clinical Trials

20 Total Publications

The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.
The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.
Journal: Journal of investigative medicine high impact case reports
Published: August 19, 2023
Similar Doctors
Experienced in Pure Red Cell Aplasia
Dr. Dulcinea D. Quintana
Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Dulcinea D. Quintana
Hematology | Oncology

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (0.7 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dulcinea Quintana is a Hematologist and an Oncologist in Albuquerque, New Mexico. Dr. Quintana is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Primary Amyloidosis, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Multiple Myeloma.

Experienced in Pure Red Cell Aplasia
Dr. Zoneddy R. Dayao
Hematology Oncology | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Zoneddy R. Dayao
Hematology Oncology | Hematology | Oncology

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (0.7 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances

Zoneddy Dayao is a Hematologist Oncology specialist and a Hematologist in Albuquerque, New Mexico. Dr. Dayao is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Experienced in Pure Red Cell Aplasia
Dr. Yang Wang
Hematology Oncology | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Yang Wang
Hematology Oncology | Hematology | Oncology

Presbyterian Healthcare Services

8300 Constitution Ave Ne, Bldg D, 
Albuquerque, NM 
 (4.2 miles away)
505-291-2200
Languages Spoken:
English, Arabic, Cantonese, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Yang Wang is a Hematologist Oncology specialist and a Hematologist in Albuquerque, New Mexico. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Paget Disease of the Breast, Acute Mountain Sickness, Multiple Myeloma, and Myelodysplastic Syndrome (MDS). Dr. Wang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rabinowitz's expertise for a condition
ConditionClose
    View All 26 Advanced Conditions
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile